Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study

作者
Steven Francis Powell,Kathryn Ann Gold,Mark Mutuota Gitau,Christopher Joseph Sumey,Michele M. Lohr,Steven C. McGraw,Ryan Kenneth Nowak,Ashley Wayne Jensen,Miran Joel Blanchard,Christopher D. Fischer,Julie Bykowski,Christie A. Ellison,Lora Jane Black,Paul A. Thompson,Juan Luis Callejas‐Valera,John H. Lee,Ezra E.W. Cohen,William Charles Spanos
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:38 (21): 2427-2437 被引量:116
标识
DOI:10.1200/jco.19.03156
摘要

PURPOSE Pembrolizumab is a humanized monoclonal antibody that blocks interaction between programmed death receptor-1 (PD-1) and its ligands (PD-L1, PD-L2). Although pembrolizumab is approved for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), its role in the management of locally advanced (LA) disease is not defined. We report a phase IB study evaluating the safety and efficacy of adding pembrolizumab to cisplatin-based chemoradiotherapy in patients with LA HNSCC. PATIENTS AND METHODS Eligible patients included those with oral cavity (excluding lip), oropharyngeal, hypopharyngeal, or laryngeal stage III to IVB HNSCC (according to American Joint Committee on Cancer, 7th edition, staging system) eligible for cisplatin-based, standard-dose (70 Gy) chemoradiotherapy. Pembrolizumab was administered concurrently with and after chemoradiotherapy with weekly cisplatin. Safety was the primary end point and was determined by incidence of chemoradiotherapy adverse events (AEs) and immune-related AEs (irAEs). Efficacy was defined as complete response (CR) rate on end-of-treatment (EOT) imaging or with pathologic confirmation at 100 days postradiotherapy completion. Key secondary end points included overall (OS) and progression-free survival (PFS). RESULTS The study accrued 59 patients (human papillomavirus [HPV] positive, n = 34; HPV negative, n = 25) from November 2015 to October 2018. Five patients (8.8%) required discontinuation of pembrolizumab because of irAEs, all of which occurred during concurrent chemoradiotherapy; 98.3% of patients completed the full planned treatment dose (70 Gy) of radiotherapy without any delays ≥ 5 days; 88.1% of patients completed the goal cisplatin dose of ≥ 200 mg/m2. EOT CR rates were 85.3% and 78.3% for those with HPV-positive and -negative HNSCC, respectively. CONCLUSION Pembrolizumab in combination with weekly cisplatin-based chemoradiotherapy is safe and does not impair delivery of curative radiotherapy or chemotherapy in HNSCC. Early efficacy data support further investigation of this approach.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
称心绿柳发布了新的文献求助10
刚刚
闰土发布了新的文献求助10
1秒前
阿努比斯的应助被ddddd采纳,获得20
1秒前
ichenjun发布了新的文献求助10
1秒前
miaojuly完成签到,获得积分10
1秒前
1秒前
柯柯完成签到,获得积分10
1秒前
长情诗蕾完成签到,获得积分10
2秒前
Teri完成签到 ,获得积分10
2秒前
绵绵驳回了sss的应助
2秒前
一叶孤舟发布了新的文献求助10
2秒前
风趣惜灵完成签到,获得积分10
2秒前
2秒前
2秒前
独特的幼菱完成签到,获得积分10
2秒前
2秒前
爱睡觉的噜噜完成签到,获得积分10
2秒前
小白发布了新的文献求助10
3秒前
朝巷发布了新的文献求助10
3秒前
Nancy发布了新的文献求助10
3秒前
XKY发布了新的文献求助10
3秒前
3秒前
Starshine完成签到,获得积分10
3秒前
马喽发布了新的文献求助10
3秒前
cdercder的应助被科研通管家采纳,获得10
4秒前
小带完成签到,获得积分10
4秒前
完美世界的应助被科研通管家采纳,获得10
4秒前
只强完成签到,获得积分10
4秒前
YONGHUMING发布了新的文献求助10
4秒前
scutljj发布了新的文献求助10
4秒前
华仔的应助被科研通管家采纳,获得10
4秒前
4秒前
隐形曼青的应助被科研通管家采纳,获得10
4秒前
4秒前
4秒前
cdercder的应助被科研通管家采纳,获得10
4秒前
4秒前
5秒前
酷酷蹇完成签到,获得积分10
5秒前
yyy完成签到,获得积分10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159633
求助须知:如何正确求助?哪些是违规求助? 9555145
关于积分的说明 21725138
捐赠科研通 7749593
什么是DOI,文献DOI怎么找? 3427281
关于科研通互助平台的介绍 2552345
邀请新用户注册赠送积分活动 2471619